PV Bulletin

Omnipod Insulin Management System Recall in Canada

Health Canada posted a recall for Omnipod Insulin Management System due to product performance issues.

Primary source: Health Canada

PV Impact Brief

Urgency: HighConfidence: high

What changed

Health Canada announced a recall for Omnipod Insulin Management System due to product performance issues.

Why it matters

Product performance issues may lead to insulin delivery errors, posing serious health risks to users.

Action needed

Identify affected lots and implement recall procedures as per Health Canada guidelines.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

action required within 24 hours

Regulatory action details

Action type
Health product recall
Publication date
2026-06-01
Safety issue
Recall for Omnipod Insulin Management System due to product performance issues.

Affected products

  • Omnipod Insulin Management System
    Insulet Corporation

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 1, 2026

Full briefing

Practical implication

Identify affected lots and implement recall procedures as per Health Canada guidelines.

Recall for Omnipod Insulin Management System due to product performance issues.

What changed: Health Canada announced a recall for Omnipod Insulin Management System due to product performance issues.

Why it matters: Product performance issues may lead to insulin delivery errors, posing serious health risks to users.

Practical implication: Identify affected lots and implement recall procedures as per Health Canada guidelines.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

Related updates for your role

publicEuropean Medicines Agency · European Union · Updated Aug 31, 2026

List of centrally authorised products with safety-related changes to the product information

Urgency: High

Review and update labeling processes in accordance with the newly published safety-related changes for affected products.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead, Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Aug 31, 2026

Guidance for industry on implementing Shortage Prevention Plans (SPP)

Urgency: High

MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicFDA · USA · Updated Aug 31, 2026

FDA Approves Treatment for Essential Thrombocythemia

Urgency: High

Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicFDA · USA · Updated Aug 31, 2026

International Collaboration to Advance New Testing Methods That Reduce Reliance on Horseshoe Crab Blood

Urgency: High

Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.

Inspection ReadinessCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward